Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · Real-Time Price · USD
2.450
-0.185 (-7.02%)
Apr 29, 2025, 4:00 PM EDT - Market closed

Lipella Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
0.540.450.180.260.96
Upgrade
Revenue Growth (YoY)
19.29%144.15%-28.99%-73.03%38.42%
Upgrade
Cost of Revenue
3.613.042.551.460.98
Upgrade
Gross Profit
-3.08-2.59-2.36-1.2-0.01
Upgrade
Selling, General & Admin
22.160.230.720.04
Upgrade
Operating Expenses
22.160.230.720.04
Upgrade
Operating Income
-5.08-4.75-2.59-1.92-0.06
Upgrade
Interest Expense
--0.01-0.01-0.01-0.01
Upgrade
Interest & Investment Income
0.060.14000
Upgrade
Other Non Operating Income (Expenses)
---00-
Upgrade
EBT Excluding Unusual Items
-5.02-4.62-2.6-1.92-0.06
Upgrade
Other Unusual Items
---0.06-
Upgrade
Pretax Income
-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income
-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income to Common
-5.02-4.62-2.6-1.87-0.06
Upgrade
Shares Outstanding (Basic)
11100
Upgrade
Shares Outstanding (Diluted)
11100
Upgrade
Shares Change (YoY)
39.69%47.84%19.15%59.91%2.46%
Upgrade
EPS (Basic)
-4.79-6.16-5.12-4.38-0.23
Upgrade
EPS (Diluted)
-4.79-6.16-5.12-4.40-0.23
Upgrade
Free Cash Flow
-3.95-3.16-1.83-0.99-0.03
Upgrade
Free Cash Flow Per Share
-3.77-4.22-3.61-2.32-0.11
Upgrade
Gross Margin
-----1.48%
Upgrade
Operating Margin
-947.23%-1055.56%-1406.26%-738.71%-5.91%
Upgrade
Profit Margin
-935.25%-1027.31%-1410.59%-719.30%-6.41%
Upgrade
Free Cash Flow Margin
-736.59%-703.85%-994.35%-381.45%-2.97%
Upgrade
EBITDA
-5.08-4.74---
Upgrade
D&A For EBITDA
00---
Upgrade
EBIT
-5.08-4.75-2.59-1.92-0.06
Upgrade
EBIT Margin
-----5.91%
Upgrade
Revenue as Reported
0.540.450.180.260.96
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q